Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial.
Buonerba C, De Placido P, Bruzzese D, Pagliuca M, Ungaro P, Bosso D, Ribera D, Iaccarino S, Scafuri L, Liotti A, Romeo V, Izzo M, Perri F, Casale B, Grimaldi G, Vitrone F, Brunetti A, Terracciano D, Marinelli A, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: bruzzese d. Front Pharmacol. 2018 Mar 16;9:189. doi: 10.3389/fphar.2018.00189. eCollection 2018. Front Pharmacol. 2018. PMID: 29615901 Free PMC article.
Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
Ferro M, Bruzzese D, Perdonà S, Mazzarella C, Marino A, Sorrentino A, Di Carlo A, Autorino R, Di Lorenzo G, Buonerba C, Altieri V, Mariano A, Macchia V, Terracciano D. Ferro M, et al. Among authors: bruzzese d. Clin Chim Acta. 2012 Aug 16;413(15-16):1274-8. doi: 10.1016/j.cca.2012.04.017. Epub 2012 Apr 20. Clin Chim Acta. 2012. PMID: 22542564
Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
Perdonà S, Bruzzese D, Ferro M, Autorino R, Marino A, Mazzarella C, Perruolo G, Longo M, Spinelli R, Di Lorenzo G, Oliva A, De Sio M, Damiano R, Altieri V, Terracciano D. Perdonà S, et al. Among authors: bruzzese d. Prostate. 2013 Feb 15;73(3):227-35. doi: 10.1002/pros.22561. Epub 2012 Jul 20. Prostate. 2013. PMID: 22821756
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
Ferro M, Bruzzese D, Perdonà S, Marino A, Mazzarella C, Perruolo G, D'Esposito V, Cosimato V, Buonerba C, Di Lorenzo G, Musi G, De Cobelli O, Chun FK, Terracciano D. Ferro M, et al. Among authors: d esposito v, bruzzese d. PLoS One. 2013 Jul 4;8(7):e67687. doi: 10.1371/journal.pone.0067687. Print 2013. PLoS One. 2013. PMID: 23861782 Free PMC article.
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy.
Arpino G, De Angelis C, Buono G, Colao A, Giuliano M, Malgieri S, Cicala S, De Laurentiis M, Accurso A, Crispo A, Limite G, Lauria R, Veneziani BM, Forestieri V, Bruzzese D, De Placido S. Arpino G, et al. Among authors: bruzzese d. Breast Cancer Res Treat. 2015 Nov;154(1):127-32. doi: 10.1007/s10549-015-3586-x. Epub 2015 Sep 30. Breast Cancer Res Treat. 2015. PMID: 26424165 Free PMC article.
Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience.
Ferro M, De Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D, Autorino R, Bottero D, Cioffi A, Matei DV, Caraglia M, Borghesi M, De Berardinis E, Busetto GM, Giovannone R, Lucarelli G, Ditonno P, Perdonà S, Bove P, Castaldo L, Hurle R, Musi G, Brescia A, Olivieri M, Cimmino A, Altieri V, Damiano R, Cantiello F, Serretta V, De Placido S, Mirone V, Sonpavde G, Terracciano D. Ferro M, et al. Among authors: bruzzese d. Medicine (Baltimore). 2015 Oct;94(42):e1861. doi: 10.1097/MD.0000000000001861. Medicine (Baltimore). 2015. PMID: 26496339 Free PMC article.
Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
Ferro M, Lucarelli G, Bruzzese D, Di Lorenzo G, Perdonà S, Autorino R, Cantiello F, La Rocca R, Busetto GM, Cimmino A, Buonerba C, Battaglia M, Damiano R, De Cobelli O, Mirone V, Terracciano D. Ferro M, et al. Among authors: bruzzese d. Oncotarget. 2017 Mar 14;8(11):18424-18434. doi: 10.18632/oncotarget.12906. Oncotarget. 2017. PMID: 27793023 Free PMC article.
221 results